Impact of selective COX-2 inhibitors on morphine-related adverse effects

	n° event/ N°patients (%)		N°	RR [95% CI]
	COX-2 inhibitors	Control	comparisons	
Resp. depression	no data	no data		
Nausea	382/896 (43)	174/443 (39)	6	1.09 [0.95 to 1.25]
Vomiting	162/915 (18)	70/460 (15)	7	1.14 [0.89 to 1.47]
Nausea and vomiting	19/107 (18)	17/71 (24)	4	0.70 [0.39 to 1.26]
Urinary retention	18/457 (3.9)	7/224 (3.1)	4	1.26 [0.53 to 2.97]
Pruritus	46/357 (13)	26/198 (13)	5	0.92 [0.58 to 1.46]
Dizziness	63/581 (11)	42/291 (14)	3	0.74 [0.52 to 1.07]
Sedation*	40/450 (8.9)	26/221 (12)	2	0.75 [0.47 to 1.20]
Bowel dysfunction**	133/487 (27)	64/239 (27)	3	1.01 [0.80 to 1.29]



RR: relative risk. CI: confidence interval. A RR <1 indicates less morphine related adverse effects with active compared with placebo. *Sedation somnolence. **Ileus or constipation or intestinal obstruction. Meta-analyses were performed when data from at least 3 trials or more than 100 patients could be combined. Individual trial data for each meta-analysis are available on http://www.hcuge.ch/anesthesie/data.htm.